Contacts

Doctor Thomas Mikeska

Quality Systems Manager, Burnet Diagnostics Initiative

Background

Thomas is an experienced Professional in Quality Management Systems and Regulatory Compliance and joined the Burnet Diagnostics Initiative as its Quality Systems Manager.

Prior to his career in Quality Management, Thomas was a Postdoctoral Researcher/Medical Scientist in the field of cancer epigenetics and genetics and has extensive experience in managing academic and commercial research projects.

Appointments

  • 2015 – 2017: Honorary Associate, School of Cancer Medicine, La Trobe University, Australia
  • 2010 – 2012: Honorary Fellow, Department of Pathology, The University of Melbourne, Australia

Positions

  • 2021 – Present: Quality Systems Manager – Burnet Diagnostics Initiative, Burnet Institute, Australia
  • 2018 – 2021: Senior Quality Assurance Specialist, National Cancer Screening Register, Telstra Health, Australia
  • 2015 – 2018: Quality Manager and Research Associate, Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Australia
  • 2012 – 2015: Senior Medical Development Scientist, Genetic Technologies, Australia
  • 2007 – 2012: Senior Postdoctoral Researcher, Molecular Pathology Research and Development, Peter MacCallum Cancer Centre, Melbourne, Australia
  • 2005 – 2007: Postdoctoral Researcher, Department of Neuropathology, University Hospital of Bonn, Germany
  • 2003 – 2005: Postdoctoral Researcher, Department of Genetics/Epigenetics, Saarland University, Germany

Qualifications

  • PhD (Biochemistry), University of Bonn, Germany
  • MSc (Chemistry), University of Bonn, Germany
  • Double Diploma of Quality Auditing and Project Management, The College for Adult Learning, Australia
  • Grade of Practitioner (PCQI), Chartered Quality Institute, United Kingdom
  • Certified Management Systems Lead Auditor, Exemplar Global, USA

Publications (41)

2018 (1)

  • Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Dale W Garsed, Kathryn Alsop, Sian Fereday, Catherine Emmanuel, Catherine J Kennedy, Dariush Etemadmoghadam, Bo Gao, Val Gebski, Valerie Gares, Elizabeth L Christie, Maartje C A Wouters, Katy Milne, Joshy George, Ann-Marie Patch, Jason Li, Gisela Mir Arnau, Timothy Semple, Sreeja R Gadipally, Yoke-Eng Chiew, Joy Hendley, Thomas Mikeska, Giada V Zapparoli, Kaushalya Amarasinghe, Sean M Grimmond, John V Pearson, Nicola Waddell, Jillian Hung, Colin J R Stewart, Raghwa Sharma, Prue E Allan, Peter F Rambau, Orla McNally, Linda Mileshkin, Anne Hamilton, Sumitra Ananda, Marisa Grossi, Paul A Cohen, Yee C Leung, Robert M Rome, Philip Beale, Penny Blomfield, Michael Friedlander, Alison Brand, Alexander Dobrovic, Martin Kobel, Paul Harnett, Brad H Nelson, David D L Bowtell, Anna deFazio
    Clin Cancer Res. 2018 Feb; 24(3):569-580

2017 (2)

2016 (2)

2015 (2)

2014 (1)

2013 (2)

2012 (4)

2011 (5)

2010 (4)

2009 (6)

2008 (3)

2007 (4)

2006 (2)

2005 (1)

2003 (2)